|Videos|July 14, 2020

Getting Younger People on PrEP

Why it's critical for the future of HIV prevention for programs like the California PrEP-AP to reach younger at-risk persons now.

Present-day HIV prevention is in an excellent spot. As discussed thoroughly in the International AIDS Society (IAS) AIDS 2020 Virtual Sessions, pre-exposure prophylaxis (PrEP) options are greatening and individualizing to the patient.

And programs including the California PrEP Assistance Program (PrEP-AP) have better bridged at-risk persons to information and means by which they can appropriately prevent HIV spread—while setting a model for other regional programs.

But what about the future of HIV prevention?

In an interview with Contagion during AIDS 2020, Philip Peters, MD, medical officer of the California Department of Public Health, discussed how programs like PrEP-AP are adapting to a new generation of HIV-risk persons—namely, by lowering its age limit to 12 years, in alignment with US Food and Drug Administration (FDA) approved marketing for PrEP.

Alongside this, they’ve made assurances that confidentiality and billing structure allows for minors and young adults on their parent’s/guardian’s health insurance would still receive the same care.

“If we can really keep looking at it from a systems standpoint—what are all the reasons people have trouble enrolling in the program—taking advantage of this benefit is hopefully going to help,” Philips said.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.